

別添5

IV. 刊行物一覽

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
針谷正祥	関節リウマチ関連リンパ増殖性疾患の診断と管理	針谷正祥	医学のあゆみ	医歯薬出版株式会社	東京	2022	761
針谷正祥	関節リウマチ関連リンパ増殖性疾患の診断と管理の手引き	3学会合同 RA 関連 LPD ワーキンググループ	関節リウマチ関連リンパ増殖性疾患の診断と管理の手引き	羊土社	東京	2022	30-45 66-87 94-111 126-133
岸本暢将	III. 関節リウマチの検査・診断:関節症候 (分担執筆)	田中良哉	日本臨牀 80 巻増刊号:最新関節リウマチ学 (第2版)	日本臨牀社	東京	2022	p. 140-144
岸本暢将	①. 「関節が痛い」はすべてリウマチ?	田中良哉	特集:ここが変わった関節リウマチの治療. 薬局, 74 (Vo3).	南山堂	東京	2023	p. 59-65
森信暁雄	ステロイドの副作用と対策	福井次矢、高木誠、小室一成総編集	今日の治療指針 2023	医学書院	日本	2023. 1	887-889
森 雅亮	関節リウマチの治療 1. 治療総論 小児, 移行期における治療戦略 - 若年性特発性関節炎に承認されている抗リウマチ薬を中心に -		日本臨牀増刊号 最新関節リウマチ学 (第2版) -寛解・治療を目指した研究と最新治療-	日本臨牀社	東京	2022	324-330

森 雅亮	特殊なケースの薬物療法 09. 成人移行期の関節リウマチ診療.	編集: 竹内勤	関節リウマチ治療 実践バイブル改訂第2版	南江堂	東京	2022	228-232
森 雅亮	第13章臨床免疫学総論. 第16章リウマチ性疾患.	監修 原 寿郎. 編集 高橋 孝雄/細井 創/齋藤昭彦.	標準小児科学第9版	医学書院	東京	2022	269-280 317-333
森 雅亮	序『小児リウマチレジデントガイド』を手にとってくださいている読者の皆様へ. Metropolitan Pediatric Rheumatology Conference	編集. 日本小児リウマチ学会 編集協力.	小児リウマチレジデントガイド	朝倉書店	東京	2022	1-241
森 雅亮. 清水 正樹	サイトカインストーム症候群. - メカニズムと治療 -	日本リウマチ学会小児リウマチ調査検討小委員会 翻訳協力.	サイトカインストーム症候群 - メカニズムと治療 -	朝倉書店	東京	2022	1-363
森 雅亮	小児リウマチ学の Controversy (編集 森 雅亮)	金子 一成 (監修・編集)	小児科診療 Controversy	中外医学社	東京	2022	468
三村 俊英. 森 雅亮. 他	成人スチル病診療ガイドライン 2017年版 [2023年 Update]	厚生労働科学研究費補助金難治性疾患等政策研究事業自己免疫疾患に関する調査研究班 編集.	成人スチル病診療ガイドライン 2017年版 [2023年 Update]	診断と治療社	東京	2023	108

森 雅亮	若年性特発性関節炎. 小児科診療ガイドライン -最新の診療指針- (第5版)	編集:加藤元博	若年性特発性関節炎. 小児科診療ガイドライン -最新の診療指針- (第5版)	総合医学社	東京	2023	644-650
森 雅亮	小児リウマチ疾患トシリズムブ治療の理論と実際	伊藤秀一. 森雅亮(監修) 協力:日本小児リウマチ学会、日本リウマチ学会	小児リウマチ疾患 トシリズムブ治療の理論と実際	メディカルレビュー社	東京	2023	201
亀田秀人, 他		日本リウマチ学会 MTX 診療ガイドライン策定小委員会.	関節リウマチにおけるメトトレキサート (MTX) 使用と診療の手引き 2023年版	未土社	東京	2023	
亀田秀人	リウマチ性疾患の臨床検査	矢崎義雄, 小室一成	内科学第12版	朝倉書店	東京	2022	1154-1182
井上有希, 亀田秀人	メトトレキサート		最新関節リウマチ学 (第2版)	日本臨床社	東京	2022	359-363
亀田秀人	解熱・鎮痛薬、抗炎症薬	堀正二, 菅野健太郎, 門脇孝, 乾賢一, 林昌洋	治療薬ハンドブック 2023	じほう	東京	2023	1188-1216
亀田秀人	MTX の効果的な使い方	竹内勤	関節リウマチ治療実践バイブル改訂第2版	南江堂	東京	2022	155-158

房間美恵	多職種連携、クリニカルパス	田中良哉	最新関節リウマチ学(第2版)	日本臨牀社	東京	2022	335-339
後藤美賀子・村島温子	妊娠希望者・妊産婦・授乳中の場合	竹内勤	関節リウマチ治療実践バイブル(改訂第2版)	南江堂		2022	348
岡本奈美	全身型若年性特発性関節炎は、他のサブタイプと異なるのか?	金子一成	小児科診療 controversy	中外医学社	東京	2022	195-201

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hirose W, Harigai M, Amano K, Hidaka T, Itoh K, Aoki K, Nakashima M, Nagasawa H, Komano Y, Nanki T.	Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis.	Rheumatol Adv Pract.	doi: 10.1093/rap/rkac090.	eCollection	2022
Tanaka E, Inoue E, Shoji A, Nilsson J, Papagiannopoulos C, Dhanda D, Yoshizawa Y, Abe M, Saka K, Sugano E, Sugitani N, Ochiai M, Yamaguchi R, Ikari K, Yamanaka H, Harigai M.	Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data.	PLoS One.	17(11):	e0277566	2022
Ishigaki K, Sakaue S, Terao C, Luo Y, Sonehara K, Yamaguchi K, Amariuta T, Too CL, Laufer VA, Scott IC, Viatte S, Takahashi M, Ohmura K, Murasawa A, Hashimoto M, Ito H, Hammoudeh M, Emadi SA, Masri BK, Halabi H, Badsha H, Uthman IW, et al.	Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis.	Nat Genet.	54(11):	1640-1651	2022
Honda S, Yano K, Tanaka E, Ikari K, Harigai M.	Development of a scoring model for the Sharp/van der Heijde score using convolutional neural networks and its clinical application.	Rheumatology (Oxford).	doi: 10.1093/rheumatology/keac586.	[Epub ahead of print]	2022

<p>Sakai R, Tanaka E, Inoue E, Sato M, Tanaka M, Ikari K, Yamanaka H, Harigai M.</p>	<p>Association between patient-reported outcomes and impairments in work and activity in patients with rheumatoid arthritis in clinical remission: a retrospective analysis using the IORRA database.</p>	<p>Mod Rheumatol.</p>	<p>doi: 10.1093/mr/roac105</p>	<p>[Epub ahead of print]</p>	<p>2022</p>
<p>Bieber T, Feist E, Irvine AD, Harigai M, Haladyj E, Ball S, Deberdt W, Issa M, Grond S, Taylor PC.</p>	<p>A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.</p>	<p>Adv Ther.</p>	<p>39(11):</p>	<p>4910-4960.</p>	<p>2022</p>
<p>Sugimoto N, Tanaka E, Inoue E, Abe M, Sugano E, Sugitani N, Saka K, Ochiai M, Higuchi Y, Yamaguchi R, Ikari K, Nakajima A, Yamanaka H, Harigai M.</p>	<p>Trends in Risks of Malignancies in Japanese Patients with Rheumatoid Arthritis: Analyses from a 14-year Observation of the IORRA Cohort.</p>	<p>Mod Rheumatol.</p>	<p>doi: 10.1093/mr/roac085</p>	<p>[Epub ahead of print]</p>	<p>2022</p>
<p>Sakai R, Tanaka E, Majima M, Harigai M.</p>	<p>Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study.</p>	<p>Arthritis Res Ther.</p>	<p>24(1):</p>	<p>135</p>	<p>2022</p>

<p>Tanaka E, Inoue E, Abe M, Saka K, Sugano E, Ochiai M, Yamaguchi R, Ikari K, Yamanaka H, Harigai M.</p>	<p>Changes in treatment adherence and behaviour during the COVID-19 pandemic in Japanese patients with rheumatoid arthritis: Results from cross-sectional study in the IORRA cohort.</p>	<p>Mod Rheumatol.</p>	<p>32(6) :</p>	<p>1193-1195</p>	<p>2022</p>
<p>Honda S, Ikari K, Yano K, Terao C, Tanaka E, Harigai M, Kochi Y.</p>	<p>Association of Polygenic Risk Scores With Radiographic Progression in Patients With Rheumatoid Arthritis.</p>	<p>Arthritis Rheumatol.</p>	<p>74(5) :</p>	<p>791-800</p>	<p>2022</p>
<p>Sugano E, Tanaka E, Inoue E, Sakai R, Abe M, Saka K, Sugitani N, Ochiai M, Yamaguchi R, Higuchi Y, Sugimoto N, Ikari K, Nakajima A, Yamanaka H, Harigai M.</p>	<p>Differences in patients' population and efficacy/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis - using the IORRA cohort.</p>	<p>Mod Rheumatol.</p>	<p>32(4) :.</p>	<p>675-685</p>	<p>2022</p>
<p>Tamura N, Azuma T, Misaki K, Yamaguchi R, Hirano F, Sugiyama E, Kanai D, Murakawa Y, Oribe M, Kimata T, Aoki K, Sugiura T, Takasugi K, Takakubo Y, Tomita Y, Isozaki T, Nanki T, Katsuyama N, Kuroiwa T, Oshikawa H, Kaneko M, Fujinaga H, et al.</p>	<p>Effectiveness and safety of subcutaneous abatacept in biologic-naïve RA patients at Week 52: A Japanese multicentre investigational study (ORIGAMI study).</p>	<p>Mod Rheumatol.</p>	<p>32(5) :</p>	<p>846-856</p>	<p>2022</p>

Harigai M, Tsuritani K, Yoshizawa Y, Atsumi T, Tanaka Y.	Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance.	Mod Rheumatol.	32(3).	:508-516	2022
Yamaguchi R, Tanaka E, Nakajima A, Inoue E, Abe M, Sugano E, Sugitani N, Saka K, Ochiai M, Higuchi Y, Sugimoto N, Ikari K, Yamanaka H, Harigai M.	Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids.	Mod Rheumatol.	32(3) :	522-527	2022
Higuchi T, Tanaka E, Inoue E, Abe M, Saka K, Sugano E, Sugitani N, Higuchi Y, Ochiai M, Yamaguchi R, Sugimoto N, Ikari K, Yamanaka H, Harigai M.	Impact of concomitant chronic kidney disease on hospitalised infections and remission in patients with rheumatoid arthritis: results from the IORRA cohort.	Mod Rheumatol.	32(5) :	875-884	2022
Sugihara T, Kawahito Y, Morinobu A, Kaneko Y, Seto Y, Kojima T, Ito, Kohno M, Nakayama T, Sobue Y, Nishida K, Matsushita I, Murashima A, Mori M, Tanaka E, Hirata S, Kishimoto M, Yamanaka H, Kojima M, Harigai M:	Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan college of rheumatology clinical practice guidelines for the management of rheumatoid arthritis.	Modern Rheumatology	32	313-322	2022

Sugihara T	Treatment strategies for elderly-onset rheumatoid arthritis in the new era.	Modern Rheumatology	32	493-499	2022
Akiyama M, Kaneko Y	Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease.	Autoimmun Rev.	May 21(5)	103056	2022
Takanashi S, Kaneko Y, Takeuchi T.	Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice.	Rheumatology (Oxford)	Nov. 3:60(11)	5247-5256	2021
Kaneko Y.	Interleukin-6 inhibitors for the treatment of adult-onset Still's disease.	Mod Rheumatol.	Jan 5:32(1)	12月15日	2022
Sobue Y, Kojima T, Ito H, Nishida K, Matsushita I, Kaneko Y, Kishimoto M, Kohno M, Sugihara T, Seto Y, Tanaka E, Nakayama T, Hirata S, Murashima A, Morinobu A, Mori M, Kojima M, Kawahito Y, Harigai M.	Does exercise therapy improve patient-reported outcomes in rheumatoid arthritis? A systematic review and meta-analysis for the update of the 2020 JCR guidelines for the management of rheumatoid arthritis.	Mod Rheumatol.	Jan 5:32(1)	96-104.	2022

Taylor PC, Alten R, Álvaro Gracia JM, Kaneko Y, Walls C, Quebe A, Jia B, Bello N, Terres JR, Fleischmann R.	Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy.	RMD Open.	Mar, 8(1)	e001994	
Uchiyama S, Takanashi S, Takeno M, Gono T, Kaneko Y, Takeuchi T, Kuwana M.	Should we reconsider the definition of elderly-onset rheumatoid arthritis in an ageing society?	Mod Rheumatol.	Feb 28;32(2)	323-329	2022
Kaneko Y, Takeuchi T.	Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still's disease.	Expert Opin Biol Ther.	Jan;22(1):	79-85.	2022
Tanemura S, Seki N, Tsujimoto H, Saito S, Kikuchi J, Sugahara K, Yoshimoto K, Suzuki K, Kaneko Y, Chiba K, Takeuchi T.	Role of interferons (IFNs) in the differentiation of T peripheral helper (Tph) cells. 2022	Int Immunol.	Sep 9;34(10):	533-544.	2022
Ito H, Murata K, Sobue Y, Kojima T, Nishida K, Matsushita I, Kawahito Y, Kojima M, Hirata S, Kaneko Y, Kishimoto M, Kohno M, Mori M, Morinobu A, Murashima A, Seto Y, Sugihara T, Tanaka E, Nakayama T, Harigai M.	Comprehensive risk analysis of postoperative complications in patients with rheumatoid arthritis for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis.	Mod Rheumatol.	Feb 28;32(2):	296-306.	2022

Tanemura S, Tsujimoto H, Seki N, Kojima S, Miyoshi F, Sugahara K, Yoshimoto K, Suzuki K, Kaneko Y, Chiba K, Takeuchi T.	Role of interferons (IFNs) in the differentiation of T peripheral helper (Tph) cells.	Int Immunol.	Sep 9;34(10)	519-532.	2022
Akiyama M, Yoshimoto K, Ishigaki S, Suzuki K, Takeuchi T, Kaneko Y.	Disease-specific expansion of CD29+IL-17RA+ T effector cells possessing multiple signaling pathways in spondyloarthritis.	Rheumatology (Oxford).	7-Jul	keac391.	2022
Ono K, Kishimoto M, Deshpande GA, Fukui S, Kawaai S, Sawada H, Matsuura M, Rodriguez VR, Proft F, Tada K, Tamura N, Taniguchi Y, Hirata A, Kameda H, Tsuji S, Kaneko Y, Dobashi H, Okano T, Haji Y, Morita A, Okada M, Komagata Y, Medina CL, Molto A, Dougados M, Hisamatsu T, Tomita T, Kaname S.	Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis.	Rheumatol Int.	Oct;42(10)	1751-1766.	2022
Tanaka E, Kawahito Y, Kohno M, Hirata S, Kishimoto M, Kaneko Y, Tamai H, Seto Y, Morinobu A, Sugihara T, Murashima A, Kojima M, Mori M, Ito H, Kojima T, Sobue Y, Nishida K, Matsushita I, Nakayama T, Yamanaka H, Harigai M.	Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis.	Mod Rheumatol.	Jan 5;32(1)	74-86.	2022

<p>Kawahito Y, Morinobu A, Kaneko Y, Kohno M, Hirata S, Kishimoto M, Seto Y, Sugihara T, Tanaka E, Ito H, Kojima T, Matsushita I, Nishida K, Mori M, Murashima A, Yamanaka H, Nakayama T, Kojima M, Harigai M.</p>	<p>Drug Treatment Algorithm and Recommendations from the 2020 update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis-Secondary Publication.</p>	<p>Mod Rheumatol.</p>	<p>Mar 16:r</p>	<p>oac017.</p>	<p>2022</p>
<p>Hanaoka H, Kikuchi J, Hiramoto K, Saito S, Kondo Y, Kaneko Y.</p>	<p>Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs.</p>	<p>Clin Kidney J.</p>	<p>Jan 31;15(7):</p>	<p>1373-1378</p>	<p>2022.</p>
<p>Kuramoto N, Saito S, Fujii T, Kaneko Y, Saito R, Tanaka M, Takada H, Nakano K, Saito K, Sugimoto N, Sasaki S, Harigai M, Suzuki Y.</p>	<p>Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: A retrospective, multicenter, case-control study.</p>	<p>Mod Rheumatol.</p>	<p>Jan 5;32(1)</p>	<p>24-31.</p>	<p>2022</p>
<p>Kaneko Y, Sakurai M, Snijder R, Kokubo S, Kato D.</p>	<p>A Retrospective, Longitudinal Study of Rheumatoid Arthritis Treatment Patterns with Janus Kinase Inhibitors and Other Disease-Modifying Antirheumatic Drugs in Japan.</p>	<p>Mod Rheumatol.</p>	<p>May 27:</p>	<p>roac046</p>	<p>2022</p>

<p>Sobue Y, Kojima M, Kojima T, Ito H, Nishida K, Matsushita I, Hirata S, Kaneko Y, Kishimoto M, Kohno M, Murashima A, Morinobu A, Mori M, Nakayama T, Sugihara T, Seto Y, Tanaka E, Hasegawa M, Kawahito Y, Harigai M.</p>	<p>Patient satisfaction with total joint replacement surgery for rheumatoid arthritis: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines.</p>	<p>Mod Rheumatol.</p>	<p>Jan 5;32(1):</p>	<p>121-126.</p>	<p>2022</p>
<p>Tanaka Y, Yamaguchi A, Miyamoto T, Tanimura K, Iwai H, Kaneko Y, Takeuchi T, Amano K, Iwamoto N, Kawakami A, Murakami M, Nishimoto N, Atsumi T, Sumida T, Ohmura K, Mimori T, Yamanaka H, Fujio K, Fujino Y, Saito K, Nakano K, Hirata S, Nakayamada S.</p>	<p>Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.</p>	<p>Rheumatology (Oxford).</p>	<p>Feb 8:</p>	<p>keac075.</p>	<p>2022</p>
<p>Tamai H, Nishina N, Kikuchi J, Izumi K, Otomo K, Yoshimoto K, Yamaoka K, Takeuchi T, Kaneko Y.</p>	<p>Serum cytokines and bone metabolic markers in patients with rheumatoid arthritis treated with biological disease modifying anti-rheumatic drugs.</p>	<p>Clin Rheumatol.</p>	<p>Sep 26.</p>		<p>2022</p>

Nakano K, Tanaka Y, Saito K, Kaneko Y, Saito S, Tanaka M, Saito R, Fujii T, Kuramoto N, Sugimoto N, Takada H, Harigai M, Sasaki S, Suzuki Y.	Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study.	Mod Rheumatol.	Jan 5;32(1)	41-49.	2022
Takada H, Kaneko Y, Nakano K, Tanaka M, Fujii T, Saito K, Sugimoto N, Sasaki S, Saito S, Saito R, Kuramoto N, Harigai M, Suzuki Y.	Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: A retrospective, multicenter, descriptive study.	Mod Rheumatol.	Jan 5;32(1) :	32-40.	2022
Saito R, Tanaka M, Ito H, Kuramoto N, Fujii T, Saito S, Kaneko Y, Nakano K, Saito K, Takada H, Sugimoto N, Sasaki S, Harigai M, Suzuki Y.	Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study.	Mod Rheumatol.	Jan 5;32(1)	50-58.	2022
Tsuboi H, Kaneko Y, Ikeda K, Aranishi T, Cai Z, Ishizuka T.	Current status of shared decision making for rheumatoid arthritis treatment in Japan: a web-based survey on physicians and patients.	Curr Med Res Opin.	May;38(5) :	853-861.	2022

<p>Tanaka H, Asakura T, Kikuchi J, Ishii M, Namkoong H, Kaneko Y, Fukunaga K, Hasegawa N.</p>	<p>Development of Rheumatoid Arthritis in Cavitary Mycobacterium avium Pulmonary Disease: A Case Report of Successful Treatment with CTLA4-Ig (Abatacept)</p>	<p>Infect Drug Resist.</p>	<p>Jan 11;15</p>	<p>91-97</p>	<p>2022</p>
<p>Takanashi S, Takeuchi T, Kaneko Y.</p>	<p>Impacts of ageing on rheumatoid factor and anti-cyclic citrullinated peptide antibody positivity in patients with rheumatoid arthritis.</p>	<p>J Rheumatol.</p>	<p>Nov 1: jrheum.</p>	<p>220526</p>	<p>2022</p>
<p>Miyamae T, Inoue E, Tanaka E, Kawabe T, Ikari K, Harigai M.</p>	<p>Association of Disease Activity Using SDAI and DAS-28, but not JADAS-27, with Subsequent Changes in Physical Function in Adult Patients with Juvenile Idiopathic Arthritis.</p>	<p>Mod Rheumatol.</p>	<p>Jun.</p>	<p>Epub ahead</p>	<p>2022</p>

<p>Narazaki H, Akioka S, Akutsu Y, Araki M, Fujieda M, Fukuhara D, Hara R, Hashimoto K, Hattori S, Hayashibe R, Imagawa T, Inoue Y, Ishida H, Ito S, Itoh Y, Kawabe T, Kitoh T, Kobayashi I, Matsubayashi T, Miyamae T, Mizuta M, Mori M, Murase A, Nakagishi Y, Nagatani K, Nakano N, Nishimura T, Nozawa T, Okamoto N, Okura Y, Sawada H, Sawanobori E, Sugita Y, Tanabe Y, Tomiita M, Yamaguchi KI, Yasuoka R, Yokoyama K.</p>	<p>Epidemiology and conduct of paediatric rheumatic diseases based on the registry database of the Pediatric Rheumatology Association of Japan.</p>	<p>Mod Rheumatol.</p>	<p>Sep.</p>	<p>of print. PMID: 36112493.</p>	<p>2022</p>
<p>Yamanaka H, Kishimoto M, Nishijima N, et al</p>	<p>Socioeconomic impact of treatment with biological disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis.</p>	<p>Mod Rheumatol Jan 11, 2023.</p>	<p>online ahead of print</p>	<p>online ahead of print</p>	<p>2023</p>
<p>Kojima M, Kawahito Y, Sugihara T, Kojima T, Harada R, Hirata S, Hashimoto M, Hidaka T, Ishikawa H, Ito H, Kishimoto M, et al</p>	<p>Late-onset rheumatoid arthritis registry study, LORIS study: study protocol and design</p>	<p>BMC Rheumatol</p>	<p>6(1)</p>	<p>90</p>	<p>2022</p>

Salinas CA, Louder A, Polinski J, Zhang TC, Bower H, Phillips S, Song Y, Rashidi E, Bosan R, Chang HC, Foster N, Gershenson B, Yamanaka H, Okishimoto M, et al.	B023 Study Consortium: Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases	Rheumatol Ther	10	201-223	2023
河野正孝、川人豊	かかりつけ医も知っておきたい関節リウマチ 関節リウマチ最新・薬物治療の実際	Clinic Magazine	49(5)	34-38	2022
Hiromu Ito, Keiichiro Nishida, Toshihisa Kojima, Isao Matsushita, Masayo Kojima, Shintaro Hirata, Yuko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Masaaki Mori, Akio Morinobu, Atsuko Murashima, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Takeo Nakayama, Hisashi Yamanaka, Yutaka Kawahito, Masayoshi Harigai	Non-drug and surgical treatment algorithm and recommendations for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication.	Modern rheumatology	33(1)	36-45	2023

<p><u>Masayo Kojima</u>, Yutaka Kawahito, Takahiko Sugihara, Toshihisa Kojima, Ryoza Harada, Shintaro Hirata, Motomu Hashimoto, Toshihiko Hidaka, Hajime Ishikawa, Hiromu Ito, Mitsumasa Kishimoto, Yuko Kaneko, Kazuo Matsui, Toshihiro Matsui, Isao Matsushita, Akio Morinobu, Keiichiro Nishida, Eiichi Tanaka, Asami Abe, Michinori Ishitoku, Shuji Asai, Takashi Kida, Akira Onishi, Satoshi Takanashi, Masayoshi Harigai</p>	<p>Late-onset rheumatoid arthritis registry study, LORIS study: study protocol and design.</p>	<p>BMC rheumatology</p>	<p>6(1)</p>	<p>90-90</p>	<p>2022</p>
<p>Yasumori Sobue, Mochihito Suzuki, Yoshifumi Ohashi, Hiroshi Koshima, Nobuyuki Okui, Koji Funahashi, Hisato Ishikawa, Hidenori Inoue, <u>Masayo Kojima</u>, Shuji Asai, Kenya Terabe, Kenji Kishimoto, Masataka Maeda, Daisuke Kihira, Shiro Imagama, Toshihisa Kojima</p>	<p>Validation of grip strength as a measure of frailty in rheumatoid arthritis.</p>	<p>Scientific reports</p>	<p>12(1)</p>	<p>21090-21090</p>	<p>2022</p>

<p>Yoshifumi Ohashi, Nobunori Takahashi, Yasumori Sobue, Mochihito Suzuki, Kyosuke Hattori, Kenji Kishimoto, Kenya Terabe, Shuji Asai, Toshihisa Kojima, <u>Masayo Kojima</u>, Shiro Imagama</p>	<p>Disease activity at baseline is an independent predictor of frailty at one year in pre-frail patients with rheumatoid arthritis; a multicenter retrospective observational study.</p>	<p>Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association</p>			2022
<p>Yasumori Sobue, Mochihito Suzuki, Yoshifumi Ohashi, Hiroshi Koshima, Nobuyuki Okui, Koji Funahashi, Hisato Ishikawa, Hidenori Inoue, <u>Masayo Kojima</u>, Shuji Asai, Kenya Terabe, Kyosuke Hattori, Kenji Kishimoto, Nobunori Takahashi, Shiro Imagama, Toshihisa Kojima</p>	<p>Locomotive syndrome in rheumatoid arthritis patients during the COVID-19 pandemic.</p>	<p>Nagoya journal of medical science</p>	84(4)	799-812	2022
<p>Yasumori Sobue, Mochihito Suzuki, Yoshifumi Ohashi, Hiroshi Koshima, Nobuyuki Okui, Koji Funahashi, Hisato Ishikawa, Hidenori Inoue, <u>Masayo Kojima</u>, Shuji Asai, Kenya Terabe, Kyosuke Hattori, Kenji Kishimoto, Nobunori Takahashi, Shiro Imagama, Toshihisa Kojima</p>	<p>Association between locomotive syndrome and methotrexate discontinuation due to adverse events in rheumatoid arthritis patients: A retrospective observational study.</p>	<p>Geriatrics & gerontology international</p>	22(10)	904-905	2022

安岡 実佳子, 肥田 武, 藤川 寛之, 永谷 祐子, 川口 洋平, 黒柳 元, 上用 祐士, 坂井 宏章, 三井 祐人, 渡邊 良太, 渡邊 美貴, 鈴木 貞夫, <u>小嶋 雅代</u>	関節リウマチ患者のフレイル予防行動の継続に関わる要因の検討 運動・食生活・社会参加の自由記述調査から	東海公衆衛生雑誌	10(1)	196-202	2022
<u>小嶋 雅代</u> , 杉原 毅彦, 松井 利浩, 田中 榮一, 小嶋 俊久, 大西 輝, 伊藤 宣, 川人 豊, 針谷 正祥	高齢発症関節リウマチの治療戦略の確立 既存疫学データによる治療実態の把握	日本老年医学会雑誌	59(Suppl.)	110-110	2022
Yoshifumi Ohashi, Nobunori Takahashi, Yasumori Sobue, Mochihito Suzuki, Kyosuke Hattori, Kenji Kishimoto, Kenya Terabe, Syuji Asai, Toshihisa Kojima, <u>Masayo Kojima</u> , Shiro Imagama	Factors Associated With Frailty in Rheumatoid Arthritis Patients With Decreased Renal Function.	Modern rheumatology			2022
Mikako Yasuoka, Toshihisa Kojima, Yuko Waguri-Nagaya, Tami Saito, Nobunori Takahashi, Shuji Asai, Yasumori Sobue, Tsuyoshi Nishiume, Mochihito Suzuki, Hiroto Mitsui, Yohei Kawaguchi, Gen Kuroyanagi, Koto Kamiji, Miki Watanabe, Sadao Suzuki, Katsunori Kondo, Toshiyuki Ojima, <u>Masayo Kojima</u>	Impact of social support on severity of depressive symptoms by remission status in patients with rheumatoid arthritis.	Modern rheumatology	32(3)	528-533	2022

平田 信太郎	【関節リウマチと周辺疾患 アンメット・メディカル・ ニーズに挑む】関節リウマ チ診療の現在 関節リウマ チの診療ガイドライン	Medical Practice	40 巻 2 号	190-197	2023. 02
平田 信太郎	【関節リウマチ治療の最前 線】生物学的製剤	医学と薬学	79 巻 8 号	1029-1038	2022. 07
平田 信太郎	【最新関節リウマチ学(第 2 版)-寛解・治癒を目指し た研究と最新治療-】特論 ドラッグホリデー	日本臨床	80 巻増刊 4 最新関 節リウマ チ学	633-637	2022. 04
平田 信太郎, 園本 格士朗	関節リウマチ(RA) 日常診療 における各種画像検査の適 切な選択、間隔、アウトカ ムとしての意義は? 超音 波・MRI は炎症評価時に適 宜、単純 X 線は治療効果判 定で 6~12 ヶ月ごとの反復 評価を推奨する	日本医事新報	5117 号	55	2022. 05
平田 信太郎	【関節リウマチの治療の現 状と問題点】生物学的製剤 の二次無効とその対策	リウマチ科	67 巻 4 号	402-406	2022. 04
Watanabe R, Murakami K, Fujisaki T, Ito H, Murata K, Yamamoto W, Fujii T, Onizawa H, Onishi A, Tanaka M, Morinobu A, Hashimoto M.	Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort.	Immunol Med.	2023 年 1 月号	1-9	2023. 1

Watanabe R, Kadoba K, Tamamoto A, Murata K, Murakami K, Onizawa H, Fujii T, Onishi A, Tanaka M, Ito H, Morinobu A, Hashimoto M.	CD8+ Regulatory T Cell Deficiency in Elderly-Onset Rheumatoid Arthritis	J Clin Med	12 卷 6 号	2342-	2023. 3
Sugimoto A, Fujimoto M, Fujii H, Takeuchi Y, Hirata M, Usui S, Nakamizo S, Ikezoe K, Ikeo S, Yamada Y, Minamiguchi S, Morinobu A, Haga H.	Fatal case of methotrexate-associated primary cutaneous extranodal NK/T-cell lymphoma of gamma delta phenotype.	Histopathology	81 卷 6 号	849-952	2022. 12.
Masui S, Yonezawa A, Yokoyama K, Iwamoto N, Shimada T, Onishi A, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Nakagawa S, Hira D, Itohara K, Imai S, Nakagawa T, Hayakari M, Matsuda S, Morinobu A, Terada T, Matsubara K.	N-terminus of Etanercept is Proteolytically Processed by Dipeptidyl Peptidase-4.	Pharm Res.	39 卷 10 号	2541-2554	2022. 10.
Iwasaki T, Watanabe R, Ito H, Fujii T, Okuma K, Oku T, Hirayama Y, Ohmura K, Murata K, Murakami K, Yoshitomi H, Tanaka M, Matsuda S, Matsuda F, Morinobu A, Hashimoto M.	Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis.	Front Immunol.	13 卷	901437	2022. 6.
森信暁雄	膠原病における分子標的薬	日本内科学会雑誌	111 卷 9 号	1829-1833	2022. 9.

森信暁雄	関節リウマチおよび膠原病のエビデンスに基づく免疫療法	臨床免疫・アレルギー科	78 巻 1 号	26-30	2022. 7
森信暁雄	開発中、申請中の標的型抗リウマチ薬	日本臨床	増刊 4 号	479-483	2022. 4
Hoshi Y, Shimizu M, Shimbo A, Yamazaki S, <u>Mori M.</u>	Overt myositis in a girl with systemic lupus erythematosus.	Pediatr Int.	64(1)	e15338	2022 Jan
Kojima M, Hasegawa M, Hirata S, Ito H, Kaneko Y, Kishimoto M, Kohno M, Kojima T, Matsushita I, <u>Mori M.</u> , Morinobu A, Murashima A, Nishida K, Seto Y, Sobue Y, Sugihara T, Tanaka E, Nakayama T, Kawahito Y, Harigai M.	Patients' perspectives of rheumatoid arthritis treatment: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines.	Mod Rheumatol.	28;32(2)	307-312	2022 Feb
Sugihara T, Kawahito Y, Morinobu A, Kaneko Y, Seto Y, Kojima T, Ito H, Kohno M, Nakayama T, Sobue Y, Nishida K, Matsushita I, Murashima A, <u>Mori M.</u> , Tanaka E, Hirata S, Kishimoto M, Yamanaka H, Kojima M, Harigai M.	Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis.	Mod Rheumatol.	28;32(2)	313-322	2022 Feb
Kondo F, Sugihara T, Umezawa N, Hasegawa H, Hosoya T, Kimura N, <u>Mori M.</u> , Yasuda S.	Associated factors with poor treatment response to initial glucocorticoid therapy in patients with adult-onset Still's disease.	Arthritis Res Ther.	29;24(1)	92	2022 Apr

<p>Shimizu M, Takei S, <u>Mori M</u>, Yachie A.</p>	<p>Pathogenic roles and diagnostic utility of interleukin-18 in autoinflammatory diseases. 2022 Sep 22;13:951535. doi: 10.3389/fimmu.2022.951535. PMID: 36211331; PMCID: PMC9537046. IF:8.786/CI:</p>	<p>Front Immunol.</p>	<p>22;13:</p>	<p>951535</p>	<p>2022 Sep</p>
<p>Narazaki H, Akioka S, Akutsu Y, Araki M, Fujieda M, Fukuhara D, Hara R, Hashimoto K, Hattori S, Hayashibe R, Imagawa T, Inoue Y, Ishida H, Ito S, Itoh Y, Kawabe T, Kitoh T, Kobayashi I, Matsubayashi T, Miyamae T, Mizuta M, <u>Mori M</u>, Murase A, Nakagishi Y, Nagatani K, Nakano N, Nishimura T, Nozawa T, Okamoto N, Okura Y, Sawada H, Sawanobori E, Sugita Y, Tanabe Y, Tomiita M, Yamaguchi KI, Yasuoka R, Yokoyama K.</p>	<p>Epidemiology conduction of paediatric rheumatic diseases based on the registry database of the Pediatric Rheumatology Association of Japan.</p>	<p>Mod Rheumatol.</p>	<p>Epub ahead of print.</p>		<p>2022 Sep</p>

Mouri M, Kanamori T, Tanaka E, Hiratoko K, Okubo M, Inoue M, Morio T, Shimizu M, Nishino I, Okiyama N, <u>Mori M.</u>	Hepatic veno-occlusive disease accompanied by thrombotic microangiopathy developing during treatment of juvenile dermatomyositis and macrophage activation syndrome: A case report.	Mod Rheumatol .	Epub ahead of print.		2022 Nov
Wakatsuki R, Shimizu M, Shimbo A, Adachi E, Kanamori T, Yamazaki S, Udagawa T, Takasawa K, Kashimada K, Morio T, <u>Mori M.</u>	Atrophic autoimmune thyroiditis complicated with systemic lupus erythematosus.	Mod Rheumatol Case Rep.	7(1)	65-67	2023 Jan
Kaneko S, Shimizu M, Miyaoka F, Shimbo A, Irabu H, Mizuta M, Nakagishi Y, Iwata N, Fujimura J, <u>Mori M.</u> , Morio T.	The dynamics of laboratory markers reflecting cytokine overproduction in macrophage activation syndrome complicated with systemic juvenile idiopathic arthritis.	Clin Immunol.	Epub ahead of print.		2023 Feb
森 雅亮	若年性特発性関節炎における疾患活動性評価. 特集 IL-6 阻害療法の基礎と臨床.	リウマチ科	69(1)	90	2023.1
森 雅亮	血管炎症候群 (川崎病, 高安動脈炎, ANCA 関連血管炎など) 特集 分子標的薬を極める.	小児内科	55(2)	213-216	2023.2
森 雅亮	膠原病・リウマチ疾患. 特集 その道のプロの経験から学ぶ 小児診療のピットフォール.	小児科	64(2)	143-151	2023.2

森 雅亮	【最新関節リウマチ学(第2版)-寛解・治癒を目指した研究と最新治療-】 関節リウマチの治療 治療総論 小児、移行期における治療戦略 若年性特発性関節炎に承認されている抗リウマチ薬を中心に	最新関節リウマチ学	80(増刊4)	324-330	2022.04
森 雅亮	IVIG 抵抗性川崎病に対するアナキンラの有効性と安全性	リウマチ科	67(4)	462-467	2022.04
森 雅亮	膠原病・リウマチ性疾患	小児科臨床	75(3)	481-486	2022.06
森 雅亮	【成人患者における小児期発症慢性疾患】 成人期における主な小児期発症疾患の病態・管理 膠原病・リウマチ性疾患・自己炎症性疾患 若年性特発性関節炎	小児内科	54(9)	1598-1604	2022.09
森 雅亮	治療法の再整理とアップデートのために. 専門家による私の治療 若年性特発性関節炎(JIA).	日本医事新報	5148	43-44	2022.12
森 雅亮	若年性特発性関節炎(JIA).	私の治療	5148	43	2022.12
川人豊	関節リウマチガイドライン2020	日本内科学会雑誌	111(3)	492-496	2022
妹尾高宏, 川人 豊.	Difficult to treat (D2T)RA とその対応を考える. 合併症を有するRA	リウマチ科	68(6)	666-672	2022
川人豊	集学的アプローチの必要性からみた整形外科リウマチ専門医のニーズ	臨床整形外科	57(7)	871-876	2022

河野正孝、川人豊	関節リウマチの治療 治療 総論 日本リウマチ学会の 診療ガイドライン	日本臨床：最 新関節リウマ チ学	80 巻	292-297	2022
Fukuda W, Kadoya M, Omoto A, Yanagida T, Isoda Y, Sunaga A, Kusuoka H, Ueno K, Morita S, Kohno M, Kawahito Y.	Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020.	Arthritis Res Ther.	24(1)	190	2022
Kawahito Y*, Morinobu A, Kaneko Y, Kohno M, Hirata S, Kishimoto M, Seto Y, Sugihara T, Tanaka E, Ito H, Kojima T, Matsushita I, Nishida K, Mori M, Murashima A, Yamanaka H, Nakayama T, Kojima M, Harigai M.	Drug Treatment Algorithm and Recommendations from the 2020 update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis- Secondary Publication.	Mod Rheumatol.	33(1)	21-35	2023
Ohashi Y et al.	Disease activity at baseline is an independent predictor of frailty at one year in pre-frail patients with rheumatoid arthritis; a multicenter retrospective observational study	J Orthop Sci	Nov 29	S0949- 2658(22)003 08-6. doi: 10.1016/j.j os.2022.10. 025.	2022
Asai S et al	Increased prevalence of Staphylococcus aureus nasal carriage in rheumatoid arthritis patients with moderate/high disease activity	J Orthop Sci.	Oct 7;	S0949- 2658(22)002 55-X. doi: 10.1016/j.j os.2022.09. 014.	2022

Sobue Y et al.	Association between locomotive syndrome and methotrexate discontinuation due to adverse events in rheumatoid arthritis patients: A retrospective observational study	Geriatr Gerontol Int.	22(10)	904-905	2022
Terabe K et al.	Reasons and Risk Factors For Discontinuation of Treatment with Any Biological Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Long-term Observational Study	Mod Rheumatol	17-Aug	doi: 10.1093/mr/roac090. Online ahead of print	2022
Ohashi Y et al.	Factors associated with frailty in rheumatoid arthritis patients with decreased renal function	Mod Rheumatol	33(2)	323-329	2023
Suzuki M et al	Influence of frailty on patient global assessment in rheumatoid arthritis.	Geriatr Gerontol Int.	22(5)	399-404	2022
Terabe K et al.	Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis	Mod Rheumatol.	33(2)	292-301	2023

<p>Tanaka Y, Takahashi T, Sumi M, Hagino O, van Hoogstraten H, Xu C, Kato N, Kameda H.</p>	<p>Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two phase 3 randomized clinical trials</p>	<p>Mod Rheumatol</p>	<p>32(4)</p>	<p>686-695</p>	<p>2022</p>
<p>Kameda H, Nishida K, Nanki T, Watanabe A, Oshima Y, Momohara S.</p>	<p>Safety and Effectiveness of Certolizumab Pegol in Japanese Patients with Rheumatoid Arthritis: Results from a 24-Week Post-Marketing Surveillance Study.</p>	<p>Mod Rheumatol</p>			<p>in press</p>
<p>Tamai H, Ikeda K, Miyamoto T, Taguchi H, Kuo CF, Shin K, Hirata S, Okano Y, Sato S, Yasuoka H, Kuwana M, Ishii T, Kameda H, Kojima T, Taninaga T, Mori M, Miyagishi H, Sato Y, Tsai WC, Takeuchi T, Kaneko Y, MIRACLE study collaborators.</p>	<p>Reduced versus maximum tolerated methotrexate dose concomitant with tumornecrosis factor inhibitor in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial.</p>	<p>Lancet Rheumatol</p>	<p>5</p>	<p>e215-e224</p>	
<p>Tanaka Y, Takahashi T, Van Hoogstraten H, Praestgaard A, Kato N, Kameda H.</p>	<p>Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab.</p>	<p>Clin Exp Rheumatol</p>			<p>in press</p>

黒江ゆり子, 房間美恵	関節リウマチとともに生きる人々のレジリエンスを支えるために—Living with Chronicity の視点から—	臨床リウマチ	34(1)	4-15	2022
Jones B, Bennett S, Larsson I, Zangi HA, Boström C, Van der Elst K, Fayet F, Fusama M, Herrero Manso MDC, Hoeper JR, Kukkurainen ML, Kwok SK, Fräzaomateus E, Minnock P, Nava T, Pavic Nikolic M, Primdahl J, Rawat R, Schoenfelder M, Sierakowska M, Voshaar M, Wammervold E, van Tubergen A, Ndosu M.	Disseminating and assessing implementation of the EULAR recommendations for patient education in inflammatory arthritis: a mixed-methods study with patients' perspectives	RMD Open	8(1)	e002256	2022
Bennett SE, Zangi HA, Larsson I, Beauvais C, Boström C, Domján A, van Eijk-Hustings Y, Van der Elst K, Fayet F, Ferreira RJO, Fusama M, Geneva-Popova M, Herrero Manso MDC, Hoeper K, Jones B, Kukkurainen ML, Gladys Kwok SK, Minnock P, Nava T, Primdahl J, Rawat R, Sierakowska M, Stoffer-Marx M, van Tubergen A, Ndosu M.	Assessing acceptability and identifying barriers and facilitators to implementation of the EULAR recommendations for patient education in inflammatory arthritis: a mixed-methods study with rheumatology professionals in 23 European and Asian countries	Ann Rheum Dis	81(10)	1348-1357	2022

<p>Narazaki H, Akioka S, Akutsu Y, Araki M, Fujieda M, Fukuhara D, Hara R, Hashimoto K, Hattori S, Hayashibe R, Imagawa T, Inoue Y, Ishida H, Ito S, Itoh Y, Kawabe T, Kitoh T, Kobayashi I, Matsubayashi T, Miyamae T, Mizuta M, Mori M, Murase A, Nakagishi Y, Nagatani K, Nakano N, Nishimura T, Nozawa T, <u>Okamoto N</u>, Okura Y, Sawada H, Sawanobori E, Sugita Y, Tanabe Y, Tomiita M, Yamaguchi KI, Yasuoka R, Yokoyama K.</p>	<p>Epidemiology and conduct of paediatric rheumatic diseases based on the registry database of the Pediatric Rheumatology Association of Japan.</p>	<p>Mod Rheum</p>	<p>doi: 10.1093/mr/roac112</p>		<p>2022</p>
<p>Takagi M, Atsumi T, Matsuno H, Tamura N, Fujii T, <u>Okamoto N</u>, Takahashi N, Nakajima A, Nakajima A, Tsujimoto N, Nishikawa A, Ishii T, Takeuchi T, Kuwana M</p>	<p>Safety and Effectiveness of Baricitinib for Rheumatoid Arthritis in Japanese Clinical Practice: 24-Week Results of All-Case Post-Marketing Surveillance</p>	<p>Mod Rheum</p>	<p>doi: 10.1093/mr/roac089</p>		<p>2022</p>
<p>岡本奈美</p>	<p>小児の慢性関節炎分類基準の歴史（総説）</p>	<p>臨床リウマチ</p>	<p>34</p>	<p>184-193</p>	<p>2022</p>

Masaki Shimizu, Kenichi Nishimura, Naomi Iwata, Takahiro Yasumi, Hiroaki Umebayashi, Yasuo Nakagishi, Yuka Okura, <u>Nami Okamoto</u> , Noriko Kinjo, Mao Mizuta, Masato Yashiro, Junko Yasumura, Hiroyuki Wakiguchi, Tomohiro Kubota, Mariko Mouri, Utako Kaneko, Masaaki Mori	Treatment for macrophage activation syndrome associated with systemic juvenile idiopathic arthritis in Japan	Int J Rheum Dis	DOI: 10.1111/1756-185X.14681		2023
岡本奈美	カナキヌマブ（JIAに承認された生物学的製剤）	日本臨床	80（増刊号）	420-425	2022
岡本奈美	若年性特発性関節炎の分類基準・診断基準	リウマチ科	67	270-278	2022
岡本奈美	フェリチン血症を伴うサイトカインストーム状態の小児において鑑別に有用なバイオマーカー	リウマチ科	68	482-491	2022
岡本奈美	拳児希望をもつ男性・女性でもリウマチ治療はできる？	薬局	74	82-85	2023